{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:08:29Z","timestamp":1778522909875,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","award":["2883"],"award-info":[{"award-number":["2883"]}],"id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","award":["609860"],"award-info":[{"award-number":["609860"]}],"id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["32848"],"award-info":[{"award-number":["32848"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.diabet.2023.101455","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T17:35:05Z","timestamp":1685727305000},"page":"101455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A glycosylated hemoglobin A1c above 6% (42 mmol\/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis"],"prefix":"10.1016","volume":"49","author":[{"given":"Kathryn J.","family":"Potter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Racine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Bonhoure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9mie","family":"B\u00e9langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ad\u00e8le","family":"Coriati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Shohoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Senior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Mailhot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4706-5170","authenticated-orcid":false,"given":"R\u00e9mi","family":"Rabasa-Lhoret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 27","key":"10.1016\/j.diabet.2023.101455_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/pedi.12732","article-title":"ISPAD clinical practice consensus guidelines 2018: Management of cystic fibrosis-related diabetes in children and adolescents","volume":"19","author":"Moran","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.diabet.2023.101455_bib0002","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101455_bib0003","article-title":"Cystic Fibrosis-Related Diabetes: Clinical approach and knowledge gaps","author":"Prentice","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.diabet.2023.101455_bib0004","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/pedi.12094","article-title":"Importance of screening with oral glucose tolerance test for early diagnosis of cystic fibrosis-related diabetes mellitus","volume":"15","author":"Noronha","year":"2014","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.diabet.2023.101455_bib0005","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/08870446.2016.1183008","article-title":"How patients' representations of cystic fibrosis-related diabetes inform their health behaviours","volume":"31","author":"Sylvain","year":"2016","journal-title":"Psychol Health"},{"key":"10.1016\/j.diabet.2023.101455_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112578","article-title":"High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study","volume":"9","author":"Scheuing","year":"2014","journal-title":"PLoS One"},{"issue":"Suppl","key":"10.1016\/j.diabet.2023.101455_bib0007","first-page":"S8","article-title":"Classification and diagnosis of diabetes","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101455_bib0008","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1515\/jpem-2017-0122","article-title":"Sensitivity and specificity of cystic fibrosis-related diabetes screening methods: which test should be the reference method?","volume":"30","author":"Boudreau","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.diabet.2023.101455_bib0009","doi-asserted-by":"crossref","first-page":"e3901","DOI":"10.1210\/clinem\/dgab384","article-title":"Combined indeterminate and impaired glucose tolerance is a novel group at high risk of cystic fibrosis-related diabetes","volume":"106","author":"Potter","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2023.101455_bib0010","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2337\/dc12-0807","article-title":"Comparison of cystic fibrosis-related diabetes with type 1 diabetes based on a German\/Austrian Pediatric Diabetes Registry","volume":"36","author":"Konrad","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101455_bib0011","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jcf.2020.11.022","article-title":"Influence of pre-diabetic and pancreatic exocrine states on pulmonary and nutritional status in adults with Cystic Fibrosis","volume":"20","author":"Potter","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.diabet.2023.101455_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.673539","article-title":"Diabetes and prediabetes in children with cystic fibrosis: a systematic review of the literature and recommendations of the Italian Society for Pediatric Endocrinology and Diabetes (ISPED)","volume":"12","author":"Mozzillo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabet.2023.101455_bib0013","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0022-3476(88)80315-9","article-title":"Diabetes mellitus associated with cystic fibrosis","volume":"112","author":"Finkelstein","year":"1988","journal-title":"J Pediatr"},{"key":"10.1016\/j.diabet.2023.101455_bib0014","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcjd.2021.03.005","article-title":"Glycated hemoglobin as a first-line screening test for cystic fibrosis\u2012related diabetes and impaired glucose tolerance in children with cystic fibrosis: a validation study","volume":"45","author":"Racine","year":"2021","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.diabet.2023.101455_bib0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcf.2015.03.013","article-title":"HbA1c as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Burgess","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.diabet.2023.101455_bib0016","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcjd.2018.04.008","article-title":"Cystic fibrosis-related diabetes screening in adults: a gap analysis and evaluation of accuracy of glycated hemoglobin levels","volume":"43","author":"Gilmour","year":"2019","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.diabet.2023.101455_bib0017","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/thx.54.1.40","article-title":"Diagnosis of cystic fibrosis related diabetes: a selective approach in performing the oral glucose tolerance test based on a combination of clinical and biochemical criteria","volume":"54","author":"Yung","year":"1999","journal-title":"Thorax"},{"key":"10.1016\/j.diabet.2023.101455_bib0018","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2016.02.005","article-title":"Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes","volume":"15","author":"Boudreau","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.diabet.2023.101455_bib0019","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s00125-021-05423-5","article-title":"Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis","volume":"64","author":"Bonhoure","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2023.101455_bib0020","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1210\/jc.2013-2756","article-title":"Impact of sex on insulin secretion in cystic fibrosis","volume":"99","author":"Coriati","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2023.101455_bib0021","first-page":"24","article-title":"\u00c9tude comparative du dosage de l'h\u00e9moglobine glyqu\u00e9e par trois m\u00e9thodes : HPLC sur G7\u00ae (Tosoh Bioscience) et D10\u00ae (Biorad), et immunoturbidim\u00e9trie sur Int\u00e9gra 800\u00ae (Roche)","author":"Szymanowicz","year":"2009","journal-title":"Immuno-analyse et biologie sp\u00e9cialis\u00e9e"},{"key":"10.1016\/j.diabet.2023.101455_bib0022","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.numecd.2020.07.044","article-title":"Abnormal glucose tolerance in a pediatric cystic fibrosis cohort: Trends in clinical outcomes and associated factors in the preceding years","volume":"31","author":"Nguyen","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.diabet.2023.101455_bib0023","unstructured":"Centers for Disease Control and Prevention NCfHS. Growth charts. 2017."},{"key":"10.1016\/j.diabet.2023.101455_bib0024","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S2213-2600(17)30472-1","article-title":"Standardisation of lung function test interpretation: Global Lung Function Initiative","volume":"6","author":"Stanojevic","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.diabet.2023.101455_bib0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1183\/09031936.00143209","article-title":"Reference values for lung function: past, present and future","volume":"36","author":"Stanojevic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.diabet.2023.101455_bib0026","first-page":"14","article-title":"Diabetes Canada 2018 clinical practice guidelines: Key messages for family physicians caring for patients living with type 2 diabetes","volume":"65","author":"Ivers","year":"2019","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.diabet.2023.101455_bib0027","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of body mass index with clinical outcomes in patients with cystic fibrosis: a systematic review and meta-analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2023.101455_bib0028","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/biom11040520","article-title":"Screening methods for diagnosing cystic fibrosis-related diabetes: a network meta-analysis of diagnostic accuracy studies","volume":"11","author":"Izs\u00e1k","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.diabet.2023.101455_bib0029","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc09-0585","article-title":"Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101455_bib0030","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/dmrr.2429","article-title":"Cystic fibrosis-related diabetes compared with type 1 and type 2 diabetes in adults","volume":"29","author":"Konrad","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.diabet.2023.101455_bib0031","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1515\/jpem-2017-0005","article-title":"Cystic-fibrosis related-diabetes (CFRD) is preceded by and associated with growth failure and deteriorating lung function","volume":"30","author":"Terliesner","year":"2017","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.diabet.2023.101455_bib0032","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2337\/dc09-1492","article-title":"Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain","volume":"33","author":"Hameed","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2023.101455_bib0033","article-title":"Cystic fibrosis related diabetes (CFRD) in the era of modulators: A scoping review","author":"Prentice","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.diabet.2023.101455_bib0034","article-title":"Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?","volume":"48","author":"Zorron","year":"2022","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.diabet.2023.101455_bib0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ppul.1143","article-title":"Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents","volume":"32","author":"Rosenecker","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.diabet.2023.101455_bib0036","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1651-2227.1994.tb13156.x","article-title":"Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections","volume":"83","author":"Lanng","year":"1994","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.diabet.2023.101455_bib0037","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcf.2015.03.001","article-title":"Characterization of patients with cystic fibrosis presenting an indeterminate glucose tolerance (INDET)","volume":"15","author":"Coriati","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.diabet.2023.101455_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246897","article-title":"Impact of 1 h oral glucose tolerance test on the clinical status of adult cystic fibrosis patients over a 4-year period","volume":"16","author":"Boudreau","year":"2021","journal-title":"PLoS One"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236362300037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236362300037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:12:17Z","timestamp":1778519537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S126236362300037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S126236362300037X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2023.101455","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A glycosylated hemoglobin A1c above 6% (42 mmol\/mol) is associated with a high risk of developing Cystic Fibrosis-Related Diabetes and a lower probability of weight gain in both adults and children with Cystic Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2023.101455","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101455"}}